The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Construction
  • Business
  • Entertainment
  • Software
  • Sports

Nattokinase Supplement for Cardiovascular and Circulatory Support
The PennZone/10270754

Trending...
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Mister Omaha Tries The Turf At Lone Star Park
  • Translational Scientist Roohid Parast Comments on FDA Approval of Icotrokinra for Psoriasis
Nattokinase Heart Health Supplement
AgeImmune's Nattokinase is one of the purest professional grade supplement on the market which is beneficial for overall heart health.

NEW YORK - PennZone -- Dr. Kanevsky, D.C. C.F.M.P. introduced a new supplement to AgeImmune's product line
earlier this May 2024.
A new addition to the family is Nattokinase supplement in a form of a vegetable capsule
each containing 2,000FU (fibrin unit) representing a unit of potency, which is equal to
100mg. Dr. Kanevsky is recommending a serving size of 2 capsules. However, if you
are in excellent heart health with no family history of blood clots, 1 capsule is enough as
a preventative measure.
Nattokinase is an enzyme derived from Japanese soybean called Natto via fermentation
process with a bacteria called Bacillus subtilis. Natto has been consumed as a
traditional food in Asia for over 2000 years and is believed to be a significant contributor

More on The PennZone
  • Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy
  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • Morrisville & Cary Education Centers Honored with National Award
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Henri-Lloyd Launches Sail Free to Break Down Barriers to Sailing

to the longevity of the Japanese people. Although natto has been consumed in Asia for
thousands of years, the fibrinolytic and antithrombolytic property of Nattokinasae was
only discovered in 1987. Recent studies demonstrated that high natto intake is
associated with decreased risk of cardiovascular disease.
This was a sufficient reason for Dr. Kanevsky to add Nattokinase to his line of products.
There is some early evidence that nattokinase may thin the blood and help break up
blood clots. This might protect against heart disease and conditions caused by blood
clots such as stroke, heart attack, and others.
Other studies show that nattokinase may help lower blood pressure and reduce
inflammation in the body.
Unlike traditional blood thinning medications, nattokinase is a natural, widely available
and inexpensive supplement with minimal to no side effects which makes is very

More on The PennZone
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Jacksonville JTB/Deerwood Park
  • Destination Niagara Launches Game Changing Digital Magazine Redefining How Visitors Experience Niagara Falls
  • Val Market is the New Frontier of the Online Marketplace
  • San Diego's newest marketing firm is boring on purpose — it's working
  • Arizona Christian Homeschools Launches Statewide Directory

attractive to Dr. Kanevsky's patients searching for an all-natural approach to their
health.
Having a large database of functional medicine patients Dr Kanevsky easily analyzed
the frequency of complains of a poor heart health, circulation, blood pressure and came
to a conclusion that Nattokinase will become one of the most popular products for
AgeImmune.
As always encapsulated without harmful excipients such as magnesium stearate, silicon
dioxide or titanium dioxide, AgeImmune's Nattokinase is one of the purest professional
grade supplement on the market.
Nattokinase supplement is derived from soy. Dr. Kanevsky warns that if you are allergic
to soy, you shouldn't be taking Nattokinase. It is currently available for purchase at a
discounted price of 21.99 on AgeImmune's website and on Amazon

Contact
AgeImmine
***@netembark.com


Source: Nattokinase Heart Health Supplement

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Rare 1933 Harold Weston painting will be auctioned to benefit the Keene Valley Library
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • HomeCentris Home Health Achieves 5-Star CMS Rating
  • Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
  • Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
  • Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
  • Cango Mobility x Hikvision Announce Strategic Partnership
  • Institute of Emerging Minds Publishes Framework for Glymphatic Clearance and Cognitive Optimization
  • HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
  • Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
  • Century Fasteners de Mexico Exhibiting at 2026 Farnborough International Airshow
  • George Martinez Completes Community Re-distribution Initiative, Returning $5,000 In Campaign Resources To Anchorage Nonprofits
  • Mister Omaha Tries The Turf At Lone Star Park
  • Andrew D. Levine Releases The Lily Network, an Indian Noir Mystery of Power, Paperwork & Murder
  • The Mapping Software Behind America's Viral Maps Just Got Faster and Smarter
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Joulescope JS320 Launches to Help Engineers Develop Battery-Powered Devices with Greater Confidence
  • Ghanaian Afrobeat Artist Praise Kusi Announces Upcoming EP "After 21:00" Releasing July 3, 2026
  • Translational Scientist Roohid Parast Comments on FDA Approval of Icotrokinra for Psoriasis

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 173
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • From Broken to Soaring Week 40
  • A Brave Little Hero with Four Paws
  • Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
  • Dave's Auto Services Sponsors Night of Racing at Action Track USA in Kutztown PA
  • Endless Mountain Music Festival Celebrates 21st Season with America250-Inspired Lineup
  • A Foundational Claim in Human Secrecy Goes Public
  • Heritage at South Brunswick Unveils Luxury Resort-Style Amenities Designed for Every Generation

Similar on PennZone

  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Sexually Abused in a Psychiatric Hospital or Psychiatrist's or Psychologist's Office? CCHR Urges Survivors to Reach Out to It
  • Ten Ten Ten Announces Free Value-Based Care Playbook for Independent Primary Care Practices
  • Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
  • Salt Lake City Families Turn to Private Autopsy Services for Faster Answers After Unexpected Loss
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • HomeCentris Home Health Achieves 5-Star CMS Rating
  • HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us